Dalton Pharma Services has entered into a contract service agreement with the United States Army Medical Materiel Development Activity (USAMMDA) in support of the US Army’s product development program for the treatment of severe or complicated malaria due to Plasmodium falciparum. Under the awarded contract with USAMMDA, Dalton will provide cGMP sterile powder filling, aseptic liquid filling, quality control release testing and ICH stability services for their anti-malarial drug development program.
Malaria remains one of the most important infectious disease threats to service members deployed to endemic areas and has a long history as the cause of disease and non-battle injury to military personnel. Despite the use of preventative measures to reduce the risk of malarial infection, service members continue to contract this disease due to operational constraints, lack of compliance, and drug-resistant malarial parasites.
“The leadership role taken by USAMMDA in the development of this important therapy for malaria treatment is to be commended, and we are privileged to support this critical program developing safe and effective anti-malarial drugs for emergency treatment protocols”, said Peter Pekos, President and CEO of Dalton.
About USAMMDA:
USAMMDA is the Department of Defense's (DoD) advanced development activity for products designed to protect and preserve the lives of Warfighters. USAMMDA develops new drugs, vaccines and medical support equipment that enhance readiness, ensures the provision of the highest quality medical care to the DoD and maximizes survival of medical casualties on the battlefield.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.